Efficacy of combination treatment with 0.05% cyclosporine A and 3% diquafosol sodium for dry eye disease

Session Details

Session Title: Presented Poster Session: Cornea – Medical

Session Date/Time: Saturday 05/09/2015 | 09:30-11:00

Paper Time: 10:30

Venue: Poster Village: Pod 4

First Author: : K.Yoon SOUTH KOREA

Co Author(s): :    J. Yang   L. Ciu   Y. Li   H. Lee   W. Choi   I. You

Abstract Details

Purpose:

To investigate the clinical efficacy of combined use of 0.05% cyclosporine A and 3% diquafosol sodium eye drops for the treatment of dry eye.

Setting:

Department of Ophthalmology, Chonnam National University Medical School, Gwangju, Korea

Methods:

Three hundred sixty eyes of 360 patients with moderate to severe inflammatory dry eye disease (DEWS grade II and III) were studied retrospectively. One hundred eighty-three patients were treated conventionally with 0.05% cyclosporine A eye drops (Group A), and 177 patients were treated with 3% diquafosol in addition to 0.05% cyclosporine A eye drops (Group B). 0.1% sodium hyaluronate artificial tears were simultaneously used in all patients. Ocular Surface Disease Index (OSDI), Tear film breakup time (BUT), Schirmer test, tear clearance rate (TCR), and ocular surface staining score were evaluated at baseline and 1, 3, and 6 months after treatment.

Results:

In group A, all clinical parameters significantly improved at 3 and 6 months after treatment compared with those at baseline. In group B, OSDI, tear film BUT, and corneal staining score significantly improved at 1, 3, and 6 months, whereas Schirmer value, TCR, and conjunctival staining score significantly improved at 3 and 6 months. Compared with group A, group B had lower OSDI and corneal staining scores and higher tear film BUT at 1 month after treatment. No significant complications were observed in both groups.

Conclusions:

In moderate to severe inflammatory dry eye, combined use of 0.05% cyclosporine A and 3% diquafosol eye drops can lead to a rapid and better improvement of symptoms, tear film instability, and corneal epithelial staining compared with conventional cyclosporine A treatment.

Financial Interest:

NONE